A Digital Therapeutic for Pain Relief through AI-Guided Visual Stimulation

通过人工智能引导视觉刺激缓解疼痛的数字疗法

• 批准号: 10561374
• 负责人: Adam Hanina
• 金额: $ 5.5万
• 依托单位: DANDELION SCIENCE CORP
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10561374
• 关键词: American; Artificial Intelligence; Behavioral; Biofeedback; Biosensor; Brain; Cellular Phone; Clinical; Color; Data; Eye; Feedback; Frequencies; Goals; Intervention; Maps; Mental disorders; Opioid Analgesics; Pain; Pain management; Patients; Pattern; Perception; Pharmacology; Phase; Photic Stimulation; Process; Randomized Controlled Trials; Signal Transduction; Small Business Innovation Research Grant; Stimulus; Tablets; Taraxacum; Testing; Therapeutic; Time; Treatment Efficacy; Writing; base; cost; design; digital treatment; nervous system disorder; neuroregulation; novel; opioid mortality; opioid sparing; pain perception; pain relief; prototype; response; visual information; visual stimulus

Project Summary Dandelion™ was founded in 2020 to develop digital therapeutics for neurologic and psychiatric disorders by interacting with the brain via the eyes. The goal of this SBIR is to design and test a safe, effective, and nonaddictive pain-relief digital therapeutic in the form of visual stimuli. The platform will use artificial intelligence (AI) and real-time biofeedback to “read” (decipher) brain signals and “write” to (neuromodulate) the brain with rapid-changing visual stimuli composed of optimized patterns, colors, and frequencies. This is the first attempt to use AI-guided visual stimuli as a treatment for pain. In 2017, 11 million of the 191 million prescriptions written for opioid pain medications were misused, and 35% of opioid-related deaths (nearly 17,000 cases) were connected to these prescriptions. In the search for safe, effective alternatives, a range of opioid-sparing interventions have been developed through pharmacologic, clinical, and digitized behavioral platforms but none has proved fully successful. Dandelion hypothesizes that the complexity and variability of pain demands a therapeutic approach that mimics the way the brain itself processes and integrates data for pain perception. Through its novel neuromodulatory platform, using artificial intelligence to parameterize potentially useful visual information, Dandelion will develop a safe, low-cost digital therapeutic that patients can view on a smartphone or tablet for immediate pain relief. By correlating stimulus with response across different types of pain, Dandelion also hopes to build a pain-perception map of wider applicability. In Phase I a prototype AI-guided platform will be developed that can synthesize novel stimulation combinations and optimize them based on feedback from an array of biosensors; their efficacy in reducing the perception of induced pain will then be tested in healthy subjects. In Phase II, Dandelion will develop the prototype into a commercially available product and test the pain-relief digital therapeutic for efficacy and generalizability in randomized controlled trials. The commercial opportunity is estimated to be $5.9 billion.

项目摘要 Danvillage ™成立于2020年，致力于开发神经和精神疾病的数字疗法， 通过眼睛与大脑互动。本SBIR的目标是设计和测试一种安全、有效、 视觉刺激形式的非成瘾性止痛数字治疗。该平台将使用人工 智能（AI）和实时生物反馈来“读取”（破译）大脑信号和“写入”（神经调节） 快速变化的视觉刺激，包括优化的模式，颜色和频率。这是 首次尝试使用人工智能引导的视觉刺激作为疼痛治疗。2017年，1.91亿人口中的1100万人 阿片类止痛药处方被滥用，35%的阿片类药物相关死亡（近 17，000例）与这些处方有关。在寻找安全、有效的替代品时， 通过药理学、临床和数字化行为学， 平台，但没有一个是完全成功的。丹泽尔假设， 疼痛需要一种治疗方法，模仿大脑本身处理和整合数据的方式， 痛觉通过其新颖的神经调节平台，使用人工智能来参数化 潜在的有用的视觉信息，丹佛斯将开发一种安全，低成本的数字治疗，患者可以 在智能手机或平板电脑上查看，立即缓解疼痛。通过将不同的刺激与反应相关联， 除了疼痛类型之外，Danvillage还希望建立一个适用范围更广的疼痛感知地图。在第一阶段a 将开发原型人工智能引导平台，可以合成新的刺激组合， 根据来自生物传感器阵列的反馈优化它们;它们在减少对 然后在健康受试者中测试诱发的疼痛。在第二阶段，丹佛斯将把原型开发成一个 市售产品，并测试疼痛缓解数字治疗的有效性和普遍性， 随机对照试验。商业机会估计为59亿美元。